Luis Fernandez de Castro Diaz

Dr. Luis Fernandez de Castro Diaz

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2021 in JBMR Plus
Verified
Journal Article
Open access
PDF file
MCMichael B Chavez
Michael B Chavez
ECEmily Y Chu
Emily Y Chu
VKVardit Kram
Vardit Kram
LDLuis Fernandez de Castro Diaz
Luis Fernandez de Castro Diaz
MSMartha J Somerman
Martha J Somerman
BFBrian Foster
Brian Foster
Micro–computed tomography (μCT) has become essential for analysis of mineralized as well as nonmineralized tissues and is therefore widely applicable in the life sciences. However, lack of standardized approaches and protocols for scanning, analyzing, and reporting data often makes it difficult to understand exactly how analyses were performed, how to interpret results, and if findings can be broadly compared with other models and studies. This problem is compounded in analysis of the dentoalveolar complex by the presence of four distinct mineralized tissues: enamel, dentin, cementum, and alveolar bone. Furthermore, these hard tissues interface with adjacent soft tissues, the dental pulp and periodontal ligament (PDL), making for a complex organ. Drawing on others' and our own experience analyzing rodent dentoalveolar tissues by μCT, we introduce techniques to successfully analyze dentoalveolar tissues with similar or disparate compositions, densities, and morphological characteristics. Our goal is to provide practical guidelines for μCT analysis of rodent dentoalveolar tissues, including approaches to optimize scan parameters (filters, voltage, voxel size, and integration time), reproducibly orient samples, define regions and volumes of interest, segment and subdivide tissues, interpret findings, and report methods and results. We include illustrative examples of analyses performed on genetically engineered mouse models with phenotypes in enamel, dentin, cementum, and alveolar bone. The recommendations are designed to increase transparency and reproducibility, promote best practices, and provide a basic framework to apply μCT analysis to the dentoalveolar complex that can also be extrapolated to a variety of other tissues of the body. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.

1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
IHIris R. Hartley
Iris R. Hartley
RGRachel I. Gafni
Rachel I. Gafni
KRKelly L. Roszko
Kelly L. Roszko
SBSydney M. Brown
Sydney M. Brown
LDLuis Fernandez de Castro Diaz
Luis Fernandez de Castro Diaz
PFPablo Florenzano
Pablo Florenzano

2 December 2021 in Bone Research
Verified
Journal Article
Open access
PDF file
LDLuis Fernandez de Castro Diaz
Luis Fernandez de Castro Diaz
BSBrian J. Sworder
Brian J. Sworder
BMByron Mui
Byron Mui
KFKathryn Futrega
Kathryn Futrega
ABAgnes Berendsen
Agnes Berendsen
PRPamela Gehron Robey
Pamela Gehron Robey
In a previous transcriptomic study of human bone marrow stromal cells (BMSCs, also known as bone marrow-derived “mesenchymal stem cells”), SFRP2 was highly over-represented in a subset of multipotent BMSCs (skeletal stem cells, SSCs), which recreate a bone/marrow organ in an in vivo ectopic bone formation assay. SFRPs modulate WNT signaling, which is essential to maintain skeletal homeostasis, but the specific role of SFRP2 in BMSCs/SSCs is unclear. Here, we evaluated Sfrp2 deficiency on BMSC/SSC function in models of skeletal organogenesis and regeneration. The skeleton of Sfrp2-deficient (KO) mice is overtly normal; but their BMSCs/SSCs exhibit reduced colony-forming efficiency, reflecting low SSC self-renewal/abundancy. Sfrp2 KO BMSCs/SSCs formed less trabecular bone than those from WT littermates in the ectopic bone formation assay. Moreover, regeneration of a cortical drilled hole defect was dramatically impaired in Sfrp2 KO mice. Sfrp2-deficient BMSCs/SSCs exhibited poor in vitro osteogenic differentiation as measured by Runx2 and Osterix expression and calcium accumulation. Interestingly, activation of the Wnt co-receptor, Lrp6, and expression of Wnt target genes, Axin2, C-myc and Cyclin D1, were reduced in Sfrp2-deficient BMSCs/SSCs. Addition of recombinant Sfrp2 restored most of these activities, suggesting that Sfrp2 acts as a Wnt agonist. We demonstrate that Sfrp2 plays a role in self-renewal of SSCs and in the recruitment and differentiation of adult SSCs during bone healing. SFRP2 is also a useful marker of BMSC/SSC multipotency, and a factor to potentially improve the quality of ex vivo expanded BMSC/SSC products.

20 February 2024 in Bone Research
Verified
Journal Article
Open access
PDF file
LDLuis Fernandez de Castro Diaz
Luis Fernandez de Castro Diaz
JWJarred M. Whitlock
Jarred M. Whitlock
ZMZachary Michel
Zachary Michel
KPKristen Pan
Kristen Pan
JTJocelyn Taylor
Jocelyn Taylor
ABAlison M. Boyce
Alison M. Boyce
Fibrous dysplasia (FD) is a rare, disabling skeletal disease for which there are no established treatments. Growing evidence supports inhibiting the osteoclastogenic factor receptor activator of nuclear kappa-B ligand (RANKL) as a potential treatment strategy. In this study, we investigated the mechanisms underlying RANKL inhibition in FD tissue and its likely indirect effects on osteoprogenitors by evaluating human FD tissue pre- and post-treatment in a phase 2 clinical trial of denosumab (NCT03571191) and in murine in vivo and ex vivo preclinical models. Histological analysis of human and mouse tissue demonstrated increased osteogenic maturation, reduced cellularity, and reduced expression of the pathogenic Gαs variant in FD lesions after RANKL inhibition. RNA sequencing of human and mouse tissue supported these findings. The interaction between osteoclasts and mutant osteoprogenitors was further assessed in an ex vivo lesion model, which indicated that the proliferation of abnormal FD osteoprogenitors was dependent on osteoclasts. The results from this study demonstrated that, in addition to its expected antiosteoclastic effect, denosumab reduces FD lesion activity by decreasing FD cell proliferation and increasing osteogenic maturation, leading to increased bone formation within lesions. These findings highlight the unappreciated role of cellular crosstalk between osteoclasts and preosteoblasts/osteoblasts as a driver of FD pathology and demonstrate a novel mechanism of action of denosumab in the treatment of bone disease.TRIAL REGISTRATION: ClinicalTrials.gov NCT03571191

24 January 2023 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
KRKelly L. Roszko
Kelly L. Roszko
LGLori Guthrie
Lori Guthrie
XLXiaobai Li
Xiaobai Li
MCMichael T. Collins
Michael T. Collins
LDLuis Fernandez de Castro Diaz
Luis Fernandez de Castro Diaz
ABAlison M. Boyce
Alison M. Boyce

1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
DODiana Ovejero
Diana Ovejero
IHIris R Hartley
Iris R Hartley
LDLuis Fernandez de Castro Diaz
Luis Fernandez de Castro Diaz
ETElizabeth Theng
Elizabeth Theng
XLXiaobai Li
Xiaobai Li
MCMichael T Collins
Michael T Collins
Parathormone (PTH) and fibroblast growth factor 23 (FGF23) both influence blood phosphate levels by regulating urinary phosphate reabsorption. Clinical data suggest that adequate renal phosphate handling requires the presence of both FGF23 and PTH, but robust evidence is lacking. To investigate whether the phosphaturic effects of PTH and FGF23 are interdependent, 11 patients with hypoparathyroidism, which features high blood phosphate in spite of concomitant FGF23 elevation, and one patient with hyperphosphatemic familial tumoral calcinosis (HFTC), characterized by deficient intact FGF23 action and resulting hyperphosphatemia, were treated with synthetic human PTH 1-34 (hPTH 1-34). Biochemical parameters including blood phosphate, calcium, intact FGF23 (iFGF23), nephrogenic cAMP, 1,25(OH)2 vitamin D (1,25D) and tubular reabsorption of phosphate (TRP), were measured at baseline, and after hPTH 1-34 treatment. In patients with hypoparathyroidism, administration of hPTH 1-34 increased nephrogenic cAMP which resulted in serum phosphate normalization followed by a significant decrease in iFGF23. TRP initially decreased and returned to baseline. In the patient with HFTC, hPTH 1-34 administration also increased nephrogenic cAMP, but this did not produce changes in phosphate or TRP. No changes in calcium were observed in any of the studied patients, although prolonged hPTH 1-34 treatment did induce supraphysiologic 1,25D levels in the patient with HFTC. Our results indicate that PTH and FGF23 effects on phosphate regulation are interdependent and both are required to adequately regulate renal phosphate handling.